New treatment for bone destruction.

摘要

Denosumab, a human monoclonal antibody to the receptor activator of nuclear factor-kappa beta ligand (RANKL), is as effective as intravenous bisphosphon-ates in suppressing bone turnover and skeletal-related events in breast-cancer-related bone metastases. Breast cancer commonly metastasises to the bones, and is characterised by increased markers of bone turnover,such as the urinary-N-telopeptide/creatinine ratio (uNTx/Cr). 255 women with breast-cancer-related bone metastases, not previously treated with intravenous bisphosphonates, were randomly assigned to denosumab (subcutaneously) or to intravenous bisphosphonate. In the denosumab group, patients received 30 mg, 120 mg, or 180 mg of denosumab every 4 weeks or 60 mg or 180 mg every 12 weeks.